Xencor (XNCR) – Press Releases
-
Xencor Appoints Bart Cornelissen as Chief Financial Officer
-
Xencor to Present at Upcoming Investor Conferences
-
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
-
Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update
-
Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy
-
Xencor to Present at the Piper Sandler 35th Annual Healthcare Conference
-
Xencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 Million
-
Xencor Reports Third Quarter 2023 Financial Results
-
Xencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual Meeting
-
Xencor to Host Third Quarter 2023 Financial Results Webcast and Conference Call on November 7, 2023
-
Xencor Announces Planned Retirement of Chief Financial Officer John Kuch
-
Xencor to Present Multiple Posters at the SITC Annual Meeting
-
Xencor Appoints Barbara J. Klencke, M.D., to Board of Directors
-
Xencor Reports Second Quarter 2023 Financial Results
-
Xencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023
-
Xencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress
-
Xencor Reports First Quarter 2023 Financial Results
-
Xencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023
-
Xencor Appoints Nancy Valente, M.D., as Chief Development Officer
-
Xencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023
-
Xencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023
-
Xencor Reports Fourth Quarter and Full Year 2022 Financial Results
-
Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023
-
Xencor to Present at the SVB Securities Global Biopharma Conference
-
Atreca and Xencor to Develop T Cell Engaging Bispecific Antibody Directed Against Novel Solid Tumor Target
-
Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates
-
Caris Life Sciences and Xencor Expand Target Discovery Collaboration for Novel XmAb® Antibody Drug Candidates
-
Xencor to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting
-
Xencor to Present at Upcoming Investor Conferences
-
Xencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb® Programs at the SITC Annual Meeting
-
Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study
-
Xencor Reports Third Quarter 2022 Financial Results
-
Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual Meeting
-
Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022
-
SpikImm, a Biotechnology Company Founded by Truffle Capital Under License from the Institut Pasteur, Announces that the Clinical Trials for SPK001, its Monoclonal Antibody Against SARS-COV-2, Have Beg
-
Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting
-
Xencor Appoints Nancy Valente, M.D., to Board of Directors
-
Xencor Reports Second Quarter 2022 Financial Results
-
Caris Life Sciences and Xencor Enter Target Discovery Collaboration and License Agreement for Novel XmAb® Bispecific Antibodies
-
Xencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call on August 3, 2022
-
Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors
-
Xencor Reports First Quarter 2022 Financial Results
-
Xencor to Host First Quarter 2022 Financial Results Webcast and Conference Call on May 5, 2022
-
Xencor Presents Data from Multiple Preclinical XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022
-
Xencor to Present Preclinical Data from XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022
-
Xencor Reports Fourth Quarter and Full Year 2021 Financial Results
-
Xencor to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 23, 2022
-
Xencor to Present at Upcoming Investor Conferences
Back to XNCR Stock Lookup
